Biom’up completes its Board of Directors with the nomination of Dr. Peter Byloos to support its international growth

Dr. Byloos possesses solid experience in the healthcare sector. Currently CEO of Optegra Eye Health Care, a UK based eye treatment company, he previously served as CEO and President of Handicare, the specialized Norwegian equipment provider for the elderly and disabled and has occupied several International Leadership positions with CR Bard, a US medical device company, where he gained extensive knowledge of the surgical hemostasis market. Dr. Byloos also worked for a few years for Gimv, the European investment firm and one of Biom’up’s historical shareholders, where he was a Partner and responsible for the development of the Health & Care platform. He is a Medical Doctor from the University of Leuven (Belgium) and holds a Master of Science in Management from the Boston University (USA).

Dr. Byloos knows the Company well, having previously represented Gimv on the Board of Directors as an Observer from 2015 to 2017.

Etienne Binant, Chief Executive Officer, commented: “I am happy to welcome Peter Byloos back to our Board of Directors. His professional qualities, wide-ranging and solid international experience in the management of companies in our sector will reinforce Biom’up’s development abroad, particularly in the United States where HEMOBLAST Bellows is successfully making inroads.”

Biom’up press release

ALL PRESS RELEASE

Caution: Federal law restricts this device to sale on or by the order of a physician. The trademark of HEMOBLAST™ Bellows and SPOT GRADE™ are the property of Biom’up. The trademarks of the products listed herein are trademarks of their respective manufacturer. Please refer to the Instructions for Use accompanying each device for further information. The presentation contains pictures owned by third party and remains their property.
E-MR-318-V1
HEMOBLAST™ Bellows Hemostatic Agent [instructions for use: E-MR-217-V6]